Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2025 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics

COLUMBUS, Ohio and CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
January 29, 2025 10:19 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer

COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
December 26, 2024 15:38 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix and Henlius Dose First Chinese Patient in Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

COLUMBUS, Ohio, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
November 02, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting

COLUMBUS, Ohio, and SAN FRANCISCO, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically...
November 02, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients

COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
October 21, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference

COLUMBUS, Ohio, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
October 01, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals’ Lasofoxifene Demonstrates Anti-Estrogen Therapy Increases Immunotherapy Efficacy by Promoting Antitumor Activity of Eosinophils

The findings were published Sept. 27 in the peer-reviewed journal Science AdvancesLasofoxifene was more effective than fulvestrant in inhibiting estrogen activity in mice models COLUMBUS, Ohio,...
August 27, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting

COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
July 18, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations

COLUMBUS, Ohio, July 18, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
June 10, 2024 10:17 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer

In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...